Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

The minutes of a meeting held at NIBSC highlighted that the issue of withdrawal was not approached purely as a scientific one, but as a question of policy that took into account concerns pertaining to economics and the perceived need to maintain the supply of fractionated blood products.

  • Read more about The minutes of a meeting held at NIBSC highlighted that the issue of withdrawal was not approached purely as a scientific one, but as a question of policy that took into account concerns pertaining to economics and the perceived need to maintain the supply of fractionated blood products.

The National Hemophilia Foundation restated its original position statement that products should be automatically recalled where a donor was diagnosed with AIDS or characteristics strongly suggestive of AIDS.

  • Read more about The National Hemophilia Foundation restated its original position statement that products should be automatically recalled where a donor was diagnosed with AIDS or characteristics strongly suggestive of AIDS.

Following the first withdrawal of products by Hyland the National Hemophilia Foundation had continued to urge its members to use factor concentrates.

  • Read more about Following the first withdrawal of products by Hyland the National Hemophilia Foundation had continued to urge its members to use factor concentrates.

At the request of the FDA, representatives of the fractionators met FDA officials to discuss the approach to be taken to future recall of products.

  • Read more about At the request of the FDA, representatives of the fractionators met FDA officials to discuss the approach to be taken to future recall of products.

Dr Ojala of Cutter sent a memo to Wilhelm Schaeffler to discuss a review of possible courses of action where donors with AIDS were discovered to have donated to plasma pools.

  • Read more about Dr Ojala of Cutter sent a memo to Wilhelm Schaeffler to discuss a review of possible courses of action where donors with AIDS were discovered to have donated to plasma pools.

Cutter stated that while it had not had to make any decisions about the disposition of a lot of Koate from a donor who developed AIDS, any decision would subsequently depend on a number of factors.

  • Read more about Cutter stated that while it had not had to make any decisions about the disposition of a lot of Koate from a donor who developed AIDS, any decision would subsequently depend on a number of factors.

Alpha's AIDS Task Force considered what to do with 11 plasma donations from a donor in Dallas who "possibly" had "some AIDS symptoms". The task force decided to release four lots of factor concentrate containing his plasma but not to use any plasma from the donor that had not yet been pooled.

  • Read more about Alpha's AIDS Task Force considered what to do with 11 plasma donations from a donor in Dallas who "possibly" had "some AIDS symptoms". The task force decided to release four lots of factor concentrate containing his plasma but not to use any plasma from the donor that had not yet been pooled.

Biological Management Committee members outlined the perceived advantages and disadvantages of anti-HBc testing in a meeting.

  • Read more about Biological Management Committee members outlined the perceived advantages and disadvantages of anti-HBc testing in a meeting.

Cutter introduced its own programme of mandatory anti-HBc surrogate testing.

  • Read more about Cutter introduced its own programme of mandatory anti-HBc surrogate testing.

Of the 11 Biological Management Committee members, 3 voted in favour of anti-HBc testing, 1 abstained and 7 voted against it.

  • Read more about Of the 11 Biological Management Committee members, 3 voted in favour of anti-HBc testing, 1 abstained and 7 voted against it.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 294
  • Page 295
  • Page 296
  • Page 297
  • Current page 298
  • Page 299
  • Page 300
  • Page 301
  • Page 302
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.